Pfizer Inc.’s $43bn acquisition of Seagen Inc. has cleared regulatory obstacles and is on track to close on 14 December, leading the company to update investors on its financial outlook and early integration plans. The company had surprises on both fronts: a 2024 financial forecast that underwhelmed investors and a reorganization that will result in the departure of chief commercial officer and biopharmaceuticals president Angela Hwang.
With Seagen Integration In Sight, Pfizer Reorganizes Commercial And R&D
The company also provided 2024 financial guidance incorporating Seagen, which underwhelmed investors.
More from Deals
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.